Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis

Capital Medical University

Status: Active, not recruiting

Conditions: Left Ventricular Remodeling; Acute Myocardial Infarction (AMI); Major Adverse Cardiovascular Event; Plasma Multi-Omics

Treatments: Other: Diagnostic Test: echocardiography and blood collection

Study type: Observational

Funder types: Other

Identifiers

NCT06885619

KS2025013

Details and patient eligibility

About

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Full description

Despite advances in AMI treatment, a substantial proportion of patients develop LVAR, leading to heart failure and increased MACE risk. Conventional biomarkers (e.g., troponin, NT-proBNP) lack sufficient predictive power for adverse outcomes. Multi-omics approaches - integrating proteomics(e.g., exosome proteomics), metabolomics, transcriptomics and lipidomics - offer a systems-level view that may uncover novel prognostic signatures.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years.
2. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
3. Willingness to provide informed consent.

Exclusion criteria

1. Prior surgery or trauma.
2. Renal failure with glomerular filtration <30 ml/min.

Trial design

1,000 participants in 1 patient group

Patients with AMI

Description:

Patients diagnosed with AMI (ST-segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation myocardial infarction \[NSTEMI\])

Treatment:

Other: Diagnostic Test: echocardiography and blood collection